articleMolecular PsychiatryFeb 21, 2006Closed access

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

NMNorbert MüllerMSMarkus SchwarzSDSandra DehningADA. DouheACAnja Cerovecki

Ludwig-Maximilians-Universität München · University of Münster

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

793
total citations
FWCI
24.28
Percentile
100%
References
38
Citations per year

Authors

13

Topics & keywords

Topics
Keywords
  • Reboxetine
  • Celecoxib
  • Placebo
  • Cyclooxygenase
  • Pharmacology
  • Medicine
  • Depression (economics)
  • Randomized controlled trial
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.